CoChat

Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited

Open access
Jerez, Andres, Gondek, Lukasz P., Jankowska, Anna M., Makishima, Hideki, Przychodzen, Bartlomiej, Tiu, Ramon V., O'Keefe, Christine L., Mohamedali, Azim M., Batista, Denise, Sekeres, Mikkael A., McDevitt, Michael A., Mufti, Ghulam J., Maciejewski, Jaroslaw P. · 2012 · Journal of Clinical Oncology
Cited by 110

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Purpose: Interstitial deletions of chromosome 5q are common in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), pointing toward the pathogenic role of this region in disease phenotype and clonal evolution. The higher level of resolution of single-nucleotide polymorphism array (SNP-A) karyotyping may be used to find cryptic abnormalities and to precisely define the topographic features of the genomic lesions, allowing for more accurate clinical correlations. Patients and Methods: We analyzed high-density SNP-A karyotyping at diagnosis for a cohort of 1,155 clinically well-annotated patients with malignant myeloid disorders. Results: We identified chromosome 5q deletions in 142 (12%) of 1,155 patients and uniparental disomy segments (UPD) in four (0.35%) of 1,155 patients. Patients with deletions involving the centromeric and telomeric extremes of 5q have a more aggressive disease phenotype and additional chromosomal lesions. Lesions not involving the centromeric or telomeric extremes of 5q are not exclusive to 5q− syndrome but can be associated with other less aggressive forms of MDS. In addition, larger 5q deletions are associated with either del(17p) or UPD17p. In 31 of 33 patients with del(5q) AML, either a deletion involving the centromeric and/or telomeric regions or heterozygous mutations in NPM1 or MAML1 located in 5q35 were present. Conclusion: Our results suggest that the extent of the affected region on 5q determines clinical characteristics that can be further modified by heterozygous mutations present in the telomeric extreme.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.36.1824

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 110

Metadata

Authors
Jerez, A., Gondek, L. P., Jankowska, A. M., Makishima, H., Przychodzen, B., Tiu, R. V., O'Keefe, C. L., Mohamedali, A. M., Batista, D., Sekeres, M. A., McDevitt, M. A., Mufti, G. J., & Maciejewski, J. P.
Venue
Journal of Clinical Oncology
Published
2012-04-20
Volume
30
Issue
12
Pages
1343-1349
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2066242053
Cited by
110
References
2
FWCI
8.84
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited. https://app.cochat.ai/papers/10.1200/jco.2011.36.1824
The paper
Jerez, A., Gondek, L. P., Jankowska, A. M., Makishima, H., Przychodzen, B., Tiu, R. V., O'Keefe, C. L., Mohamedali, A. M., Batista, D., Sekeres, M. A., McDevitt, M. A., Mufti, G. J., & Maciejewski, J. P. (2012). Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.36.1824

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.